2023 World Conference on Lung Cancer (Posters)-EP11.02. First Line Sintilimab plus Anlotinib vs Platinum-based Chemotherapy in Metastatic NSCLC (SUNRISE): Updated Efficacy and Safety Analysis

EP11.02. First Line Sintilimab plus Anlotinib vs Platinum-based Chemotherapy in Metastatic NSCLC (SUNRISE): Updated Efficacy and Safety Analysis - PDF(Slides)

Back to course

Pdf Summary

The SUNRISE study compared the efficacy and safety of the combination of sintilimab and anlotinib versus platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC). The study enrolled a total of 99 patients and the primary endpoint was objective response rate (ORR). After a final analysis, the combination therapy showed a statistically significant improvement in ORR compared to chemotherapy (49.0% vs 28.0%). The combination therapy also showed a longer median duration of response (21.4 months vs 13.0 months) and progression-free survival (11.8 months vs 5.6 months) compared to chemotherapy. The combination therapy had a manageable safety profile, with lower rates of treatment-related adverse events and immune-related adverse events compared to chemotherapy. Based on these findings, the authors suggest that the combination of sintilimab and anlotinib could be a potential option for first-line treatment of metastatic NSCLC.

Asset Subtitle

Tianqing Chu

Meta Tag

Speaker Tianqing Chu

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

SUNRISE study

efficacy

safety

combination therapy

sintilimab

anlotinib

platinum-based chemotherapy

metastatic non-small cell lung cancer

objective response rate

progression-free survival